WO2023056481A1 - Méthodes et systèmes automatisés d'identification rapide de particules cibles - Google Patents

Méthodes et systèmes automatisés d'identification rapide de particules cibles Download PDF

Info

Publication number
WO2023056481A1
WO2023056481A1 PCT/US2022/077477 US2022077477W WO2023056481A1 WO 2023056481 A1 WO2023056481 A1 WO 2023056481A1 US 2022077477 W US2022077477 W US 2022077477W WO 2023056481 A1 WO2023056481 A1 WO 2023056481A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
fluorophore
sample
target
conjugate
Prior art date
Application number
PCT/US2022/077477
Other languages
English (en)
Inventor
David A. BAUNOCH
Tim Bruemmer
Michael L. OPEL
Natalie Luke
Original Assignee
CAP Diagnostics, LLC, dba Pathnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CAP Diagnostics, LLC, dba Pathnostics filed Critical CAP Diagnostics, LLC, dba Pathnostics
Publication of WO2023056481A1 publication Critical patent/WO2023056481A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria

Definitions

  • the present invention is related to automated flow cytometry-based methods and systems for rapid detection of target particles, e.g., cells or other particles.
  • the methods and systems herein may be applied to rapid identification of infectious agents (e.g., cells, viral particles, etc.) in samples.
  • the systems may also integrate automated antibiotic susceptibility testing and other aspects of sample preparation, processing, and/or incubation.
  • Infectious diseases can affect multiple organs systems and are responsible for significant morbidity, mortality, and economic impact.
  • the present invention features flow cytometry-based methods and systems for rapidly identifying target particles such as a cell or other particles, or multiple distinct target particles (e.g., cells or other particles) in a sample containing a plurality of targets.
  • target particles such as a cell or other particles, or multiple distinct target particles (e.g., cells or other particles) in a sample containing a plurality of targets.
  • the present invention features flow cytometry-based methods and systems for rapidly identifying one or more infectious agents (e.g., cells, viral particles, etcxx in a sample.
  • the systems and methods may also feature quantifying said target particles (e.g. cells or other particles such as but not limited to infectious agents).
  • the system may also feature, identifying the presence of an active infection and/or determining if the infectious agents are alive.
  • Detection of whether or not the infectious agents are alive may be achieved using a separate label, distinguishable from the other labels used in the assay, for identification.
  • the system has the ability to perform and integrate antibiotic susceptibility testing and/or other aspects of sample preparation, processing, and/or incubation.
  • the present invention features methods and flow cytometry systems wherein the data analysis utilizes fluorophore-labeled antibodies specific to antigens which appear in abundance preferentially on each one of the various target particles of interest (e.g., cells or other particles, such as but not limited to infectious agents of interest). While the present invention discloses the term “fluorophore” in detail, the use of the term “fluorophore” in present invention includes detectable moieties such small organic dyes, tandem dyes, polymer dyes, phycobiliproteins, etc., and the present invention is not limited to said detectable moieties. The use of quantum dots, other dyes, or other appropriate detectable moieties is within the scope of the present invention.
  • the identification of the target particle is based on the identification of the dominantly abundant antibody conjugate.
  • the dominant antibody-fluorophore conjugate in an event
  • X represents a minimum abundance ratio and is associated with the antibody.
  • X may be, for example, at least >1, or approximately 2, 3, 4, 5, 6, 7, 8, 9, 10, 10+, etc.
  • the present invention features flow cytometry-based methods and systems for rapidly identifying one or more target particles, such as a cell or other particle, in a sample.
  • the present invention provides flow cytometry systems and methods for identifying one or more infectious agents in a sample.
  • the present invention features a system configured to analyze optical data captured by a flow cytometer, wherein the data captured by the flow cytometer is from a detection system therein that detects optical emission as a target particle passes through the flow cytometer.
  • the optical emission is derived from one or a combination of: (i) one or more fluorophores each conjugated to an antibody bound to the target particle, the antibody being one of n antibody species each specific for one of n target particles, the one or more fluorophores being from a group of m total fluorophores used for labeling the n antibody species forming a pool of / antibody-fluorophore conjugates, and (ii) potential autofluorescence associated with the target particle.
  • the system comprises a processor; and a memory component operatively connected to the processor and configured to store an application, wherein the application allows the processor to identify a dominant antibody-fluorophore conjugate on each target particle using an unmixing algorithm, the dominant antibody-fluorophore conjugate being an antibody-fluorophore conjugate that appears in abundance preferentially on the target particle due to its binding to the target particle.
  • the unmixing algorithm either: uses a single minimum abundance ratio (X) value using the smallest minimum value of X for any of the antibody-fluorophore conjugates constraining the solution to require a dominant antibody fluorophore-conjugate with abundance value of at least X times that of the next most abundant antibody-fluorophore conjugate as a requirement for an acceptable solution for a closed form unmixing algorithm or as a constraint on a numerical mixing algorithm; or partitions the analysis into n separate instances, wherein n is the number of possible target particles that can be identified in the analysis, wherein each instance has a unique minimum abundance ratio requirement based on a predetermined value of X for each antibody-fluorophore conjugate, the minimum abundance ratio requirement being a requirement that a particular dominant antibody-fluorophore conjugate have an abundance value greater than X times that of the next most abundant antibody-fluorophore conjugate in order to be a correct solution for a closed form expression and wherein the minimum abundance ratio requirement is an additional
  • the abundance value for the dominant antibody-fluorophore conjugate is generally required to be above a predetermined threshold level of fluorescence.
  • the residual error of the numerical analysis is generally below a threshold value or below a specific fraction of a next closest residual error value in order to be considered a valid unambiguous result.
  • the systems described herein are capable of detecting and quantifying a plurality of different targets, e.g., at least 10 different targets, at least 15 different targets, at least 20 different targets, at least 25 different targets, etc., within a single sample.
  • the minimum abundance ratio (X) is at least >1 for each antibody-fluorophore conjugate. In some embodiments, the minimum abundance ratio (X) is from 1 to 10 for at least one antibody-fluorophore conjugate. In some embodiments, the minimum abundance ratio (X) is from 3 to 10 for at least one antibody-fluorophore conjugate. In some embodiments, the minimum abundance ratio (X) is from 5 to 20 for at least one antibody-fluorophore conjugate.
  • each target particle has a predetermined autofluorescence signature.
  • this autofluorescence signature is added as an additional fluorophore paired with the respective minimum abundance ratio (X) for the target particle in that instance.
  • the autofluorescence signatures may be added as an additional fluorophore for purposes of fitting measured spectra in the numerical analysis.
  • each antibody is conjugated with a single unique fluorophore.
  • the pool of / antibody-fluorophore conjugates comprises n different antibodies each labeled with a unique fluorophore.
  • the pool of / antibody-fluorophore conjugates comprises n different antibodies, a portion of which are each labeled with one fluorophore and a portion of which are each labeled with two or more fluorophores.
  • the system can identify a maximum number of particles equal to the sum of all of the terms m!/((m-k)! *k!) for all k from 1 to m using m fluorophores. In some embodiments, the system can identify 3 distinct target particles using 2 fluorophores. In some embodiments, the system can identify 7 distinct target particles using 3 fluorophores.
  • the minimum abundance ratio requirement is that each of the k fluorophores used to label an antibody for a particular target has an abundance ratio to all other m-k fluorophores that is greater than approximately X/k and wherein X is the minimum abundance ratio for the target particle when all of its target antibody is labeled with a single fluorophore.
  • the flow cytometer is a spectral flow cytometry system.
  • the system is operatively connected to the flow cytometer.
  • the system is integrated with the flow cytometer.
  • the target particle is a cell or particle.
  • the cell or particle is or is associated with an infectious agent.
  • the infectious agent is a bacterium, a virus, a fungus, or a parasite.
  • the antibodies are each specific for an infectious agent. In some embodiments, the antibodies are monoclonal antibodies.
  • the present invention features a system configured to analyze optical data captured by a flow cytometer, wherein the data captured by the flow cytometer is from a detection system therein that detects optical emission as a particle passes through the flow cytometer, the optical emission being derived from one or a combination of: (i) one or more fluorophores each conjugated to an antibody bound to the particle, the one or more fluorophores being from a pool of / antibody-fluorophore conjugates, and (ii) autofluorescence associated with the particle.
  • the system comprises a processor; and a memory component operatively connected to the processor and configured to store an application.
  • the application configures the processor to identify the dominant fluorophores on each target particle using an unmixing algorithm, the dominant k fluorophores being the fluorophores that appears in abundance preferentially on the target particle, wherein k is the number of fluorophore-antibody conjugates used to label a particular target and wherein k can be a value from 1 to r wherein r is the number of a set of fluorophores used in various unique combinations to label any single target and r is less than or equal to m.
  • the unmixing algorithm partitions the analysis into n separate instances, wherein n is the number of possible target particles that can be identified in the analysis, wherein each instance has a unique minimum abundance ratio requirement based on a predetermined value of X for each antibody-fluorophore conjugate, the minimum abundance ratio requirement being a requirement that a particular dominant fluorophore conjugate has an abundance value greater than X times that of the next most abundant fluorophore in order to be a correct solution for a closed form expression and wherein the minimum abundance ratio requirement is an additional constraint for a numerical solution.
  • the present invention features a system configured to analyze optical data captured by a flow cytometer, wherein the data captured by the flow cytometer is from a detection system therein that detects optical emission as a particle passes through the flow cytometer, the optical emission being derived from one or a combination of: (i) one or more fluorophores each conjugated to an antibody bound to the particle, the one or more fluorophores being from a pool of / antibody-fluorophore conjugates, and (ii) autofluorescence associated with the particle.
  • the system comprises a processor; and a memory component operatively connected to the processor and configured to store an application.
  • the application configures the processor to identify a dominant fluorophore on each target particle using an unmixing algorithm, the dominant fluorophore being a fluorophore that appears in abundance preferentially on the particle.
  • the unmixing algorithm uses a single minimum abundance ratio (X) value using the smallest minimum value of X for any of the antibody-fluorophore conjugates constraining the solution to require a dominant antibody fluorophore-conjugate with abundance value of at least X times that of the next most abundant antibody-fluorophore conjugate as a requirement for an acceptable solution for a closed form unmixing algorithm or as a constraint on a numerical mixing algorithm.
  • the present invention also features antibody-fluorophore conjugates for use in identifying one or more target particles or target cells in a sample with a system according to the disclosures herein.
  • the antibody of the antibody-fluorophore conjugate is specific for a particular target particle or target cell and the fluorophore of the antibody-fluorophore conjugate is a fluorophore with an emission spectra further distinguished from other similar fluorophore spectra in the analysis by the autofluorescence of the target particle or target cell.
  • the antibody of the antibody-fluorophore conjugate is specific for a particular target particle or target cell and the fluorophore of the antibody-fluorophore conjugate is selected so that it is: (a) a weak or dim fluorophore if the antibody binds to its target particle or target cell at a relative high binding density; (b) a strong or bright fluorophore if the antibody binds to its target particle or target cell at a relative low binding density; (c) a medium intensity fluorophore if the typical antibody binding to the target particle or target cell is not at a relative high binding density and not at a relative low binding density.
  • the antibody of the antibody-fluorophore conjugate is specific for a particular infectious agent and the fluorophore of the antibody-fluorophore conjugate isselected so that it is: (a) a weak or dim fluorophore if the antibody binds to its infectious agent at a relative high binding density; (b) a strong or bright fluorophore if the antibody binds to its infectious agent at a relative low binding density; (c) a medium intensity fluorophore if the typical antibody binding to the infectious agent is not at a relative high binding density and not at a relative low binding density.
  • the present invention also includes flow cytometry panels for use with the systems described in the present invention, wherein the panel comprises a plurality of antibody-fluorophore conjugates according to the disclosures herein.
  • the present invention also features an automated system for identifying one or more infectious agents in a sample, wherein the system comprises a flow cytometry unit and a processing system for analyzing data from the flow cytometry unit according to the disclosures herein.
  • the system further comprises an antibiotic susceptibility testing (AST) unit for determining susceptibility and resistance of the one or more infectious agents in the sample to one or more concentrations of one or more antimicrobial agents.
  • the AST unit comprises a multiwell plate wherein a plurality of wells are loaded with a particular concentration of one or more antimicrobial agents.
  • the AST unit further comprises a dispensing system for dispensing a portion of the sample into at least one well of the multiwell plate.
  • the AST unit is operatively connected to the processing system, the processing system further comprises an application stored by the memory for execution by the processor, the application determines the order in which wells are analyzed for susceptibility or resistance. In some embodiments, the application determines an order in which wells are analyzed that will likely result in the fewest wells needed to be analyzed in order to get all necessary information for providing a minimum inhibitory concentration (MIC) for one or more of the antimicrobial agents. In some embodiments, the application accesses a database comprising data that provides the application a probability of resistance (PR) for one or more concentrations of the one or more antimicrobial agents. In some embodiments, the system determines which wells to analyze first based on the provided p R values.
  • PR probability of resistance
  • the application uses conditional probabilities to minimize the number of wells that need to be analyzed, wherein the application calculates the probability of resistance of the one or more infectious agents to a certain antimicrobial agent (A) at a certain concentration based on the resistance of the one or more infectious agents to another antimicrobial agent (B) at a particular concentration.
  • the system further comprises an incubation unit comprising one or more incubators for housing and incubating a portion of the sample.
  • the system further comprises a preparation unit for accepting the sample and preparing the sample for processing through the flow cytometry unit.
  • the system is for identifying an active infection with one or more infectious agents in the sample.
  • the infectious agent is a bacteria, a virus, a fungus, or a parasite.
  • the infectious agent is Acinetobacter baumannii, Actinotignum schaalii, Aerococcus urinae, Aerococcus urinae, Alloscardovia omnicolens, Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, Chlamydia, Citrobacter freundii, Citrobacter koseri, Clostridium difficile, Corynebacterium riegelii, Klebsiella aerogenes, Enterococcus faecalis, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Mycobacterium tuberculosis, Mycoplasm
  • the system is configured for parallel processing of samples.
  • the system may be fully automated.
  • the system can process at least 5, at least 10, at least 20, at least 40, at least 50, etc., samples per day.
  • the system processes the sample by dispensing portions into one or more multiwell plates.
  • the system can transport the multiwell plate between the sample preparation unit and the incubator and the sample preparation unit and the analysis unit.
  • the system can centrifuge the multiwell plate and aspirate supernatant.
  • the system can aliquot liquid into wells of the multiwell plate and resuspend pelleted material.
  • the multiwell plate comprises wells having different concentrations of various antimicrobial agents to facilitate susceptibility analysis.
  • the system first identifies the infectious agent in the sample and optionally subsequently subjects the sample to antibiotic susceptibility testing. The system may be configured to minimize the number of wells analyzed by the flow cytometer based on identification of the infectious agent and prioritization of wells analyzed.
  • the sample is a urine sample, a blood sample, a CSF sample, a respiratory swap sample, a nasal swab sample, an abscess sample, an ascites sample, a cyst sample, a Lavine swab sample, a sepsis sample.
  • the system further comprises one or more buffers. In some embodiments, the system further comprises one or more growth mediums. In some embodiments, the system further comprises one or more centrifuges.
  • the system further comprises a plurality of binding molecules, the binding moieties being conjugated with a detectable moiety.
  • the binding molecules are antibodies or binding fragments.
  • the detectable moiety is a dye (e.g., fluorescent dye, label) or other label. In some embodiments, the system allows for detection of at least 20 different fluorescent dyes.
  • the system is organized into a sample preparation unit for accepting the sample, an incubation unit, and an analysis unit, the analysis unit comprising the flow cytometry unit, wherein the sample can move between both the incubation unit and the sample processing unit, and the sample can move between the analysis unit and the sample processing unit.
  • the system comprises one or more computer processing units.
  • one or more of the computer processing units are operatively connected to the sample processing unit, the incubation unit, the analysis unit, or a combination thereof.
  • the computer processing unit comprises a microprocessor and one or more memory components, wherein at least one of the memory components comprises computer readable instructions for the microprocessor.
  • the computer readable instructions allow the microprocessor to regulate movement of the sample within or between the sample processing unit, the incubation unit, and analysis unit.
  • the computer processing unit is configured to analyze results from the flow cytometer so as to provide identity of one or more infectious agents in the sample.
  • the systems and methods herein may also feature quantification of infectious agents, identification of the presence of an active infection, determining if infectious agents are alive, etc.
  • the systems and methods herein may also have the ability to perform and/or integrate antibiotic susceptibility testing, sample preparation, sample processing, incubation, the like, or a combination thereof.
  • the system comprises an analysis unit, e.g., a flow cytometry unit or the component of the system that identifies (or allows for identification of) one or more infectious agents in the sample, quantifies (or allows for the quantification of) the infectious agents in the sample, identifies (or allows for identification of) one or more markers on or in the infectious agents in the sample, etc.
  • the analysis unit or flow cytometry unit may feature an integrated processing system for analyzing data (e.g., from the flow cytometer) and providing results such as the identity of the one or more infectious agents, the number of the one or more infectious agents, the identity of the one or more markers, etc.
  • the system may further comprise a preparation unit, e.g., a component of the system that prepares a sample for the analysis unit, e.g., flow cytometry analysis.
  • the system further comprises an incubation unit, e.g., a component of the system that may function to store, hold, retain, or promote the growth of the sample (e.g., infectious agents in the sample).
  • the preparation unit and/or analysis unit and/or incubation unit may be operatively linked, e.g., wherein a sample can be moved from one unit to another. As an example, a sample may be inserted into the preparation unit. From the preparation unit, the sample may move to the analysis unit.
  • the sample may move from the preparation unit to the incubation unit. In certain embodiments, the sample moves from the incubation unit back to the preparation unit. In some embodiments, the sample may move from the analysis unit back to the preparation unit. In some embodiments, the system is a fully automated system.
  • the system may further comprise one or more buffers, one or more growth mediums, one or more centrifuges, one or more waste containers, one or more incubators, etc.
  • the system may comprise a magnetic separation rack if the system utilizes isolation using magnetic bead separation techniques.
  • the system may further comprise (e.g., store) one or more antibodies conjugated with detectable dyes or labels, e.g., fluorescent labels.
  • the system may also feature components for storing one or more reagents, components for measuring and/or dispensing one or more reagents to the sample, components for transporting the sample or a portion thereof from one unit to another unit, and/or components for transporting the sample or a portion thereof from one location to another within a unit.
  • Such components for sample transportation, storing of buffers and reagents, dispensing buffers and reagents, etc. are well known to one of ordinary skill in the art.
  • the system further comprises processing units, memory units, and computer-implemented instructions for carrying out the methods herein and computer-implemented instructions for analyzing signals obtained from the analyzing unit.
  • m refers to the total number of fluorophores used
  • n refers to the total number of targets to be identified (and thus also the total number of antibodies (antibody species));
  • / refers to the total number of unique antibody conjugates and / is greater than or equal to n;
  • r refers to the number of fluorophores in a shared set of fluorophores and r is less than or equal to m;
  • k is an index and represents an instance of a unique subset of the set of r (potentially up to m) fluorophores used; and
  • i is a general index typically used for instances of targets.
  • Flow cytometry The present disclosure generally pertains to various embodiments of flow cytometry-based systems and methods. Basic information on flow cytometry can be found in numerous references, such as Shapiro's Practical Flow Cytometry, Third Edition (Alan R. Liss, Inc. 1995), which is incorporated by reference herein in its entirety. Although the basic principles of flow cytometry are known to those of ordinary skill in the art, Applicants believe that the embodiments presented in the present disclosure are currently unknown in the art.
  • Flow cytometry can be used to measure one or more optical or electrical parameters of cells or other particles that pass through a light beam (e.g., a laser).
  • a fluid sample to be analyzed is introduced from a sample tube into or near the center of a faster flowing stream of sheath fluid, which carries the fluid sample toward the center of the combined streams, hydraulically compressing the sample and causing the cells or other particles in the sample volume to columnate.
  • This process allows the cells or other particles to be delivered to the center of the measuring point in an examination zone.
  • a laser beam is focused on the cells or other particles as they pass through the examination zone.
  • Detectors that are optically connected to the examination zone interrogate signals from this zone on one or more detection channels.
  • certain signals are generated and sensed by detectors.
  • the detectors utilize a plurality of detection channels. For instance, these signals include forward scatter intensity, which provides information concerning the size of individual cells or other particles. Another common signal is side scatter intensity, which provides information regarding the granularity (relative size, proportions, and refractive properties) of the cells or other particles.
  • Other signals can include fluorescence emissions from one or more fluorescent dyes and/or fluorescent molecules associated with cells or other particles.
  • Flow cytometers may include spectral flow cytometers having many more detection channels for different spectral emissions bands enabling a much larger number of unique fluorescent measurements than the number of fluorescent labels used to identify particles or cells, or other flow cytometer configurations, which are well known to one of ordinary skill in the art.
  • Flow cytometry systems typically feature fluidics systems, optics systems, and electronics systems.
  • the fluidics system of a flow cytometer is responsible for transporting samples from the sample tube to the flow cell. Once through the flow cell (and past the laser), the sample is either sorted (in the case of cell sorters) or transported to waste.
  • the components of the optical system may include excitation light sources, lenses, and filters used to collect and move the light around the instrument and the detection system that generates the photocurrent and/or counts photons. This information can be acted on in real time and/or saved for further analysis.
  • spectral flow is its ability to make finer distinctions between emitters so that a larger set of labels can be used and distinguished in a single analysis.
  • labels are created by conjugating fluorophores with antibodies specific to target antigens that may appear on the particles or cells to be analyzed. Appropriate fluorophore-antibody pairing can be used to advantage in certain defined applications.
  • infectious agent refers to an organism, agent, or entity that produces an infection.
  • Infectious agents may include but are not limited to bacteria, viruses, fungi, protozoa, bacteria, or a combination thereof.
  • Non-limiting examples of infectious agents that may be tested for in the present invention include but are not limited to one or a combination of: Acinetobacter baumannii, Actinotignum schaalii, Aerococcus urinae, Aerococcus urinae, Alloscardovia omnicolens, Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, Chlamydia, Citrobacter freundii, Citrobacter koseri, Clostridium difficile, Corynebacterium riegelii, Klebsiella aerogenes, Enterococcus faecalis, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella
  • Enterococcus group e.g., Enterococcus faecalis, Enterococcus faecium
  • Escherichia coli Finegoldia magna
  • Human Herpes Virus -1,-2 HSV -1,-2
  • Human Herpes Virus -5 CMV
  • Human Herpes Virus -6 HHV-6
  • JC Virus Kingella kingae
  • Klebsiella group e.g., Klebsiella oxytoca, Klebsiella pneumoniae
  • Morganella morganii Mycobacterium group (e.g., Mycobacterium tuberculosis), Mycoplasma hominis
  • Pantoea agglomerans Peptostreptococcus group (e.g., Peptostreptococcus prevotii, Peptostreptococcus micros, Peptostreptococcus tetradius, etc.), Peptoni
  • the present invention is not limited to the infectious agents disclosed herein.
  • antibiotic refers to a compound or molecule for the purpose of killing or inhibiting the growth of an infectious agent.
  • Antibiotics may herein be referred to as antimicrobial agents and/or anti-bacterial agents, or vice versa.
  • antibiotics include, but are not limited to, penicillins, tetracyclines, cephalosporins, quinolones, lincomycins, macrolides, sulfonamides, glycopeptide antibiotics, aminoglycosides, carbapenems, ansamycins, lipopeptides, monobactams, nitrofurans, oxazolidinones, and polypeptides.
  • Penicillin antibiotics include, but are not limited to, penicillin, methicillin, amoxicillin, ampicillin, flucloxacillin, penicillin G, penicillin V, carbenicillin, piperacillin, ticarcillin, oxacillin, dicloxacillin, azlocillin, cioxacillin, mezlocillin, temocillin, and nafcillin. Additionally, penicillin antibiotics are often used in combination with beta-lactamase inhibitors to provide broader spectrum activity; these combination antibiotics include amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, and clavulanate/ticarcillin.
  • Tetracycline antibiotics include, but are not limited to, tetracycline, doxycycline, demeclocycline, minocycline, and oxytetracycline.
  • Cephalosporin antibiotics include, but are not limited to, cefadroxil, cephradine, cefazolin, cephalexin, cefepime, ceftaroline, loracarbef, cefotetan, cefuroxime, cefprozil, cefoxitin, cefaclor, ceftibuten, ceftriaxone, cefotaxime, cefpodoxime, cefdinir, cefixime, cefditoren, ceftizoxime, cefoperazone, cefalotin, cefamandole, ceftaroline fosamil, ceftobiprole, and ceftazidime.
  • Cephalosporin antibiotics are often used in combination with beta-lactamase inhibitors to provide broader spectrum activity; these combination antibiotics include, but are not limited to, avibactam/ceftazidime and ceftolozane/tazobactam.
  • Quinolone antibiotics include, but are not limited to, lomefloxacin, ofloxacin, norfloxacin, gatifloxacin, ciprofloxacin, moxifloxacin, levofloxacin, gemifloxacin, cinoxacin, nalidixic acid, trovafloxacin, enoxacin, grepafloxacin, temafloxacin, and sparfloxacin.
  • Lincomycin antibiotics include, but are not limited to, clindamycin and lincomycin.
  • Macrolide antibiotics include, but are not limited to, azithromycin, clarithromycin, erythromycin, telithromycin, dirithromycin, roxithromycin, troleandomycin, spiramycin, and fidaxomicin.
  • Sulfonamide antibiotics include, but are not limited to, sulfamethoxazole, sulfasalazine, mafenide, sulfacetamide, sulfadiazine, silver sulfadiazine, sulfadimethoxine, sulfanilamide, sulfisoxazole, sulfonamidochrysoidine, and sulfisoxazole.
  • Sulfonamide antibiotics are often used in combination with trimethoprim to improve bactericidal activity.
  • Glycopeptide antibiotics include, but are not limited to, dalbavancin, oritavancin, telavancin, teicoplanin, and vancomycin.
  • Aminoglycoside antibiotics include, but are not limited to, paromomycin, tobramycin, gentamicin, amikacin, kanamycin, neomycin, netilmicin, streptomycin, and spectinomycin.
  • Carbapenem antibiotics include, but are not limited to, imipenem, meropenem, doripenem, ertapenem, and imipenem Zcilastatin.
  • Ansamycin antibiotics include, but are not limited to, geldanamycin, herbimycin, and rifaximin.
  • Lipopeptide antibiotics include, but are not limited to, daptomycin.
  • Monobactam antibiotics include, but are not limited to, aztreonam.
  • Nitrofuran antibiotics include, but are not limited to furazolidone and nitrofurantoin.
  • Oxaxolidinone antibiotics include, but are not limited to, linezolid, posizolid, radezolid, and torezolid.
  • Polypeptide antibiotics include, but are not limited to, bacitracin, colistin, and polymyxin B.
  • antibiotics which are not part of any of the above-mentioned groups include, but are not limited to, clofazimine, dapsone, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifampicin, rifabutin, rifapentine, streptomycin, arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin/dalfopristin, thiamphenicol, tigecycline, tinidazole, and trimethoprim.
  • the present invention is not limited to the antimicrobial agents, e.g., antibiotics or other drugs, disclosed herein.
  • the present invention is not limited to the infectious agents disclosed herein.
  • the scope of the presently disclosed methods and systems encompasses the inclusion of antibiotics, antimicrobials, or antibacterial agents not yet known, or not yet approved by regulatory authorities.
  • the present invention is not limited to the antibiotics, antimicrobials, or antibacterial agents disclosed herein.
  • FIG. 1 shows a schematic view of the system of the present invention.
  • the present invention is not limited to the components or configurations therein.
  • FIG. 2 shows a schematic view of the system of the present invention.
  • the present invention is not limited to the components or configurations therein.
  • FIG. 3 shows an example of an ABX plate for antibiotic susceptibility testing (AST).
  • AST antibiotic susceptibility testing
  • FIG. 4 shows a schematic view of methods and workflows utilizing the system of the present invention.
  • the present invention is not limited to the component, configurations, methods, or workflows therein.
  • the present invention features flow cytometry-based methods and systems for rapid identification of one or more target particles (e..g, cells or other particles, such as but not limited to infectious agents) in a sample.
  • the methods and systems herein can quantify specific cells or particles in samples.
  • the methods and systems herein detect the presence of active infections.
  • the methods and systems herein determine antibiotic susceptibility of infectious agents to one or more antimicrobial agents (e.g., the pooled antibiotic susceptibility of the combination of the infectious agents to one or more antimicrobial agents) in the sample.
  • the methods and systems herein help reduce or eliminate the need for empirical testing.
  • the systems and methods herein may be fully automated, thereby eliminating the need for a user to perform steps after the raw sample or a preprocessed sample is introduced to the system.
  • the infectious agent is a bacteria. In some embodiments, the infectious agent is a virus. In some embodiments, the infectious agent is a fungus. In some embodiments, the infectious agent is a parasite.
  • the infectious agent is Acinetobacter baumannii, Actinotignum schaalii, Aerococcus urinae, Aerococcus urinae, Alloscardovia omnicolens, Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, Chlamydia, Citrobacter freundii, Citrobacter koseri, Clostridium difficile, Corynebacterium riegelii, Klebsiella aerogenes, Enterococcus faecalis, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Pantoea agglomerans, Proteus mirabilis, Providencia stuartii,
  • the sample may be a biological sample, e.g., a sample derived from a patient or subject.
  • the sample is a urine sample, a blood sample, a CSF sample, a respiratory swap sample, a Levine swab, a nasal swab sample, an abscess sample, an ascites sample, a cyst sample, a sepsis sample, a biopsy, etc.
  • the present invention is not limited to the aforementioned examples of samples.
  • the methods herein may feature sample preparation prior to flow cytometry analysis.
  • the sample e.g., a portion of the sample
  • the sample is centrifuged and ultimately resuspended and stained, e.g., incubated with a pool of antibody-fluorophore conjugates specific for a panel of targets, e.g., infectious agents.
  • the sample may be centrifuged and washed one or multiple times after incubation with the pool of antibody-fluorophore conjugates prior to flow cytometry analysis.
  • the present invention is not limited to preparation of the sample using centrifugation and washes.
  • the system uses magnetic bead separation techniques.
  • a portion of the sample may be used for antibiotic susceptibility testing (AST).
  • the methods and systems herein may feature sample preparation prior to inoculation of the ABX plate for antibiotic susceptibility testing (AST).
  • AST antibiotic susceptibility testing
  • a portion of the sample may be prepared (e.g., centrifuged and washed, subjected to magnetic bead separation techniques, etc.) and/or incubated in growth media prior to inoculation of the ABX plate.
  • the methods and systems herein feature a data analysis method that utilizes fluorophore-labeled antibodies (antibody-fluorophore conjugates) specific to antigens located on or in target particles (e.g., cells or other particles, such as but not limited to infectious agents) which appear in abundance preferentially on each one of the various target particles of interest (e.g., cells or other particles of interest).
  • target particles e.g., cells or other particles, such as but not limited to infectious agents
  • target particle refers to a target cell or other target particle.
  • An antibody can be created to bind preferentially, e.g., via specificity for antigen on or in the target cell or target particle.
  • the present invention describes spectral flow cytometry and the use of spectral flow cytometers.
  • spectral flow cytometers include Cytek Aurora, SONY SA3800, and Invitrogen Bigfoot. See also U.S. Pat. No. 7.280,204, U.S. Pat. App. No. 2013/0346023, U.S. Pat. No. 9,128,955, and Novo et al., Cytometry 2013 83(5): 508-520, the disclosures of which are incorporated in their entirety herein by reference.
  • the present invention includes methods for selecting fluorophores for particular antibodies to prepare the antibody-fluorophore conjugates.
  • antibody-fluorophore conjugates may be prepared based on a variety of criteria which, among others, may include: the known probabilities that various target particles (e.g., infectious agents) will appear together in sample (e.g., a patient sample), the similarities and differences between the fluorophores to be selected from, the degree of specificity of the antibody for its target particle, the degree of non-specific binding of the antibody on the various non-target particles or other non-targets, the intensity of the fluorophore, and/or the intensity and the spectra of the autofluorescence associated with the target particle and/or its target antibody.
  • target particles e.g., infectious agents
  • a portion of the sample is incubated with the appropriate pool of antibody-fluorophore conjugates.
  • a single portion of the sample is incubated with all of the desired antibody-fluorophore conjugates to be used in the assay.
  • the antibody-fluorophores are split into two or more groups, wherein a portion of the sample is incubated with the first group of antibody-fluorophore conjugates and a portion of the sample is incubated with the second pool of antibody fluorophore conjugates.
  • the present invention is not limited to splitting the antibody-fluorophore conjugates into two groups.
  • the antibody-fluorophore conjugates are split into three groups for three flow cytometry runs.
  • the antibody-fluorophore conjugates are split into four groups for four flow cytometry runs, etc.
  • the overall particle or cell concentration of the sample is not known, it may be beneficial to prepare dilutions of the sample, e.g., where the goal would be to prepare a dilution that has a concentration that will be acceptable for flow cytometric analysis.
  • two dilutions are prepared for each group of antibody-fluorophore conjugates.
  • three dilutions are prepared for each group of antibody-fluorophore conjugates.
  • the present invention is not limited to three dilutions.
  • three wells are prepared for each group of antibody-fluorophore conjugates. The first well may reflect the concentration that is nominally the original sample concentration, and the second two wells may be, for example, 1/10 and 1/100 the original sample concentration.
  • the methods feature initial measurements to assess the cell concentration prior to automatic dilution, and then the sample can be diluted (or not) accordingly to optimize analysis on the cytometer.
  • Antibodies are selected for a given type of target particle (e.g., cell or other particle) to a target antigen specific to that target particle (e.g., cell or other particle) type.
  • target particle e.g., cell or other particle
  • the antibodies are typically specific to target antigens that may be conserved across multiple variants of that species and for which there is minimal binding (specific or otherwise) with the other particles of interest in the analysis.
  • Fluorophores may be selected such that they can each be differentiated via spectral flow cytometry.
  • each target particle is intended to be identified with a unique fluorophore, however the present invention is not limited to this configuration.
  • the present invention also includes the identification of a number of targets with a fewer number of different fluorophores than the number of targets by utilizing combinations of sets of fluorophores.
  • the fluorophores may be paired (conjugated) with the various antibodies based on a set of criteria in order to augment differentiation for each event and normalize the intensity of the target fluorophore for each target particle (e.g., cell or other particle).
  • target particle e.g., cell or other particle
  • the criteria may include one or the following: the degree of labeling (DOL) of the fluorophores onto the conjugated antibodies, which may be kept relatively low to preserve the binding specificity of the target antibody to the specific antigen of the target particle; the brightness of the fluorophore may generally be inversely proportional to binding selectivity of the target antibody versus those of the non-target antibodies for the particular target particle; the criteria described above (re: DOL of the fluorophores to the conjugated antibodies being kept relatively low) may be augmented by adjusting for antibody binding density on the target particle, for example, dimmer fluorophores may be conjugated with target antibodies with higher binding densities to normalize overall intensity of the event; and/or autofluorescence of the target particle or its target antibody may be used to augment differences between similar fluorophores so that a target particle or antibody with a distinctive and significant autofluorescence spectra may have its target antibody conjugated with a fluorophore with distinctly different spectra than the autofluorescence of the target particle but which also has
  • factors that may affect which fluorophore is chosen for a particular antibody may include the autofluorescence signature of the target and/or its target antibody, the brightness or dimness of the fluorophore, the abundance of the corresponding antigen on the target particle, the growth curve of the target particle (e.g., cell).
  • the fluorophore is generally chosen to help enhance resolution of the possible target particles.
  • the identification of the target particle is primarily based on the identification of the dominantly abundant antibody-fluorophore conjugate on the target particle.
  • the flow cytometer features an analysis system configured to utilize an unmixing algorithm that incorporates an additional constraint on the acceptable solution set, e.g., a minimum abundance ratio requirement.
  • This constraint may (in part) be determined by the relative specificity of a given conjugate for the specific antigen on its target particle. For example, the constraint may be that the solution must be such that the abundance of the most highly abundant fluorophore is greater than X times the next most abundant fluorophore in order for its conjugate antibody’s targeted particle to be a candidate solution.
  • X refers to the minimum abundance ratio and is associated with the antibody.
  • the dominant fluorophore for any single event has an abundance that is greater than X times any of the other fluorophore abundances wherein X is at least greater than 1, e.g., a minimum abundance ratio requirement wherein X is a single value representing the minimum realized selectivity ratio across all of the fluorophore conjugates when binding to their respective target particle.
  • the value of X does not have to be precise; it needs to be large enough to eliminate ambiguous solutions due to noise and unaccounted for autofluorescence while being small enough to allow for the existence of likely amounts of a non-target binding as can be measured a priori, e.g., by exposing a given target particle to a cocktail of all (/) antibody conjugates for n target particles of interest to determine the appropriate value to assign.
  • this constraint can be employed in n instances of the numerical optimization, wherein n equals the number of different antibodies which is typically equal to the number of potential target particles (e.g., infectious agents) to be identified.
  • target particles e.g., infectious agents
  • the constraint can be employed uniquely in 20 instances of the numerical optimization.
  • X may be dependent on the conjugate’s (antibody’s) relative selectivity for its target particle. Based on prior measurements, the system can assign a particular value for X for each antibody-fluorophore conjugate representing its antibody conjugate binding selectivity.
  • the system can assign a value for X for each of: Fluorophore A (antibody-fluorophore conjugate A), Fluorophore B (antibody-fluorophore conjugate B), Fluorophore C (antibody-fluorophore conjugate C), Fluorophore D (antibody-fluorophore conjugate D), Fluorophore E (antibody-fluorophore conjugate E), Fluorophore F (antibody-fluorophore conjugate F), Fluorophore G (antibody-fluorophore conjugate G), Fluorophore H (antibody-fluorophore conjugate H), Fluorophore I (antibody-fluorophore conjugate I), Fluorophore J (antibody-fluorophore conjugate J), Fluorophore K (antibody-fluorophore conjugate K), Fluorophore L (antibody-fluorophore A (antibody-fluorophore conjugate A), Fluor
  • each of Fluorophores A-Z have a unique value for X.
  • a portion of Fluorophores A-Z have a unique value for X.
  • a single X value can be utilized. In this case, the single value of X chosen would be the minimum of all of the A-Z X values.
  • X is greater than 1 so that there is always a single dominant antibody-fluorophore conjugate. While X may be more likely to be on the order of 10 or more, there may be circumstances wherein X is less than 10, which can still allow the ability to uniquely identify a target particle. In the case where an X value for a given antibody-fluorophore conjugate approaches 1 (or for cases in which it is helpful to accommodate autofluorescence of some or all antibody conjugates) it may be beneficial to use separate instances of constraints on X and in this case X values can potentially be lower than in the single instance calculation.
  • X for a particular antibody-fluorophore conjugate may be less than 1. In some embodiments, X for a particular antibody-fluorophore conjugate may be 1 or about 1. In some embodiments, X for a particular antibody-fluorophore conjugate is 2 or about 2. In some embodiments, X for a particular antibody-fluorophore conjugate is 3 or about 3. In some embodiments, X for a particular antibody-fluorophore conjugate is 4 or about 4. In some embodiments, X for a particular antibody-fluorophore conjugate is 5 or about 5. In some embodiments, X for a particular antibody-fluorophore conjugate is 6 or about 6.
  • X for a particular antibody-fluorophore conjugate is 7 or about 7. In some embodiments, X for a particular antibody-fluorophore conjugate is 8 or about 8. In some embodiments, X for a particular antibody-fluorophore conjugate is 9 or about 9. In some embodiments, X for a particular antibody-fluorophore conjugate is 10 or about 10. In some embodiments, X for a particular antibody-fluorophore conjugate is more than 10, e.g., about 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. In some embodiments, X for a particular antibody-fluorophore conjugate is from 1-2. In some embodiments, X for a particular antibody-fluorophore conjugate is from 2-3.
  • X for a particular antibody-fluorophore conjugate is from 3-4. In some embodiments, X for a particular antibody-fluorophore conjugate is from 4-5. In some embodiments, X for a particular antibody-fluorophore conjugate is from 5-6. In some embodiments, X for a particular antibody-fluorophore conjugate is from 6-7. In some embodiments, X for a particular antibody-fluorophore conjugate is from 7-8. In some embodiments, X for a particular antibody-fluorophore conjugate is from 8-9. In some embodiments, X for a particular antibody-fluorophore conjugate is from 9-10. The present invention is not limited to the aforementioned values for X.
  • the system can be configured to help rule out false positives with use of the known value of X that is appropriate in order to give a certain level of confidence in the result based on knowledge of the relative binding characteristics of the conjugates.
  • X can be different for each target conjugate so that the criteria represents an array of values relating to each possible target particle identification. In some embodiments, e.g., for a closed form solution, this can be applied after the fact to see if a valid identification has been made.
  • this can also be applied as a constraint in the numerical analysis, in which case the analysis could be done for each of n possible outcomes where n is the number of possible targets for identification.
  • the measured abundance of ⁇ in that instance ( ⁇ , being associated with the assigned antibody-fluorophore conjugate for a Type 1 particle) must meet the constraint that it is greater than X 1 times any other abundance a 2 through a m , wherein m is the number of all of the different fluorophores used for labeling in the assay and X, is an approximate predetermined value for X for the antibody for a Type 1 particle.
  • a mechanism for addressing the autofluorescence in the presence of particle types with different autofluorescence spectra is to premeasure (and store) the form of the autofluorescence spectra for each particle type individually.
  • the system may be configured to assign an autofluorescence signature (S) for each target particle (e.g., infectious agent).
  • the autofluorescence signatures (S) are each unique for each target (e.g., infectious agent), however the present invention is not limited to each target having a unique fluorescence signature (S).
  • This autofluorescence spectra may be added as an additional fluorophore in the analysis with its own unknown abundance.
  • An optimization formulation requiring a numerical solution can be performed by the imposition of the abundance requirement (using X) paired with the addition of the appropriate autofluorescence spectra S, as an additional fluorophore and use of an appropriate numerical approach to solve each of the n problems to determine the best fit.
  • This approach can be coupled with elimination of many of the possible solutions by examination of the measured spectra using certain key measurements (e.g., distinct characteristics for each target fluorophore) to identify incompatibility with the minimum abundance ratio requirement immediately.
  • This may take the form of identifying absolute intensities or threshold ratios of intensity at or between key measurements (spectral ranges excited by various lasers) for the given fluorophore, z, and noting when these are not sufficient for i to possibly be the dominant fluorophore. For example, if the spectra for fluorophore i has a peak intensity at a certain detected range (e.g., 704 - 736 nm when excited by a violet laser) and a relatively low intensity peak in this range is observed compared to the other detected intensities in the actual measurement, then i cannot be the dominant fluorophore resulting in that spectra.
  • a certain detected range e.g., 704 - 736 nm when excited by a violet laser
  • a set of elimination criteria can be used in evaluating the observed spectral measurement to quickly rule out a portion of the n possible fluorophores.
  • the methods herein are advantageous because a different autofluorescence signature can be evaluated for each separate instance of the numerical optimization. This autofluorescence signature will be that of the corresponding target particle, antigen, cell, etc.
  • n instances can be executed in parallel with the one with the lowest residual error determining the identity of the particle, antigen, cell, etc. (e.g., infectious agent). If not executed in parallel, the analysis may be further reduced by evaluating key characteristics of the measured spectra to eliminate non-viable dominant fluorophores prior to unmixing.
  • the concept of the minimum realized selectivity ratio can be used to select target antibodies that have very high values of X and provide an array of conjugates for each of these using a set of 2 or more different fluorophores.
  • the total number of distinct particles that could be identified with m fluorophores would be the sum of all the terms m!/((m-k)!k!) for all k from 1 to m.
  • the number of particles that the system can identify using a subset of r fluorophores is the sum of each of the terms r!/((r-k)!*k!) for all k from 1 to r, wherein r can be less than or equal to m.
  • k fluorophores with k equal to at least 1 and less than or equal to r (wherein r is the number of a set of fluorophores used in various combinations to uniquely identify various targets) to identify a given target
  • r is the number of a set of fluorophores used in various combinations to uniquely identify various targets
  • a portion of the antibody for that target would be labeled separately by one each of the k fluorophores, and then these would be combined to provide the total number of antibodies that would have been used if labeled by a single fluorophore, e.g., the total conjugates for that antibody would be made up of a fractions of approximately 1/k of the total antibody separately labeled with one each of the k fluorophores.
  • Vs of the antibody for Target A is labeled with a first fluorophore
  • Vs of the antibody for Target A is labeled with a second fluorophore
  • Vs of the antibody for Target A is labeled with a third fluorophore.
  • the final stained target particle would have approximately 1/k (Vs in the example of Target A) of each of these k fluorophores bound thereon in dominant abundance over any other fluorophores used to label conjugates and having an X value for each that is approximately Vs of X A (wherein X A is the minimum realized selectivity ratio of the single fluorophore labeled antibody for Target A).
  • Target B, C and D separate subsets of 2 of the same set of 3 fluorophores can be used to separately label their corresponding antibodies creating a target criteria with 2 fluorophores having dominant and roughly equal abundances over all other fluorophores used to stain targets in which the minimum realized selectivity ratio for the fluorophores in each pair is approximately 1 ⁇ 2 of the corresponding ratio, X i for each of the single fluorophore labeled antibodies for Targets B, C and D respectively.
  • 1 of each of the set of 3 fluorophores used for Target A can be used, one each, to label the corresponding antibodies for Targets E, F and G creating target criteria for identifying each which is approximately the same as it would have been if all antibodies were labeled with a single unique fluorophore.
  • the original value of X, for a given antibody should be relatively high as the new value for a fluorophore on the target particle labeled with k fluorophores will be 1/k of the original and there will be additional non-specific binding of the same fluorophores used on other target particles (labeling other antibodies) which may reduce it further.
  • the minimum abundance ratios for each fluorophore when labeled with k fluorophores are each approximately X i /k and the minimum abundance ratio requirement would take the form of the conjugate requirement that ai > X i /k AND a 2 > X i /k ...AND a k >X i /k).
  • Each of the abundances of the k fluorophores would be about equal and must all be greater than X/k times each of the other m-k fluorophores used to label other targets.
  • Fluorophores may only be combined in this way for antibodies with relatively high minimum realized selectivity (large values of X) because of this dilution. In this way, it is possible to use only 4 fluorophores to distinguish 15 different target particles, and it is also possible, for example, to use two sets of 3 fluorophores to distinguish 7 targets each (totaling 14 targets detectable with the 2 sets of 3 fluorophores) plus another set of 6 fluorophores to be individually used to distinguish 6 additional targets with lower X values, yielding an assay that can detect 20 different targets distinguishable with a total of 12 fluorophores (without diluting the 6 with lowest X values or allowing 6 to be used uniquely in conjunction with significant target or target antibody autofluorescence, for example.,
  • the system may be configured to ignore non-target particles, e.g., non-target cells, depending on the application, without interfering with the identification or counting of the target particles of interest (e.g., cells or other particles such as but not limited to infectious agents).
  • target particles of interest e.g., cells or other particles such as but not limited to infectious agents.
  • large cells e.g., as detected from forward scatter
  • non-target cells such as red blood cells, white blood cells, etc.
  • the system of the present invention can also be physically tuned, e.g., aspects of the flow cytometer such as but not limited to the filters, laser intensities, detector gains, etc., can be adjusted and optimized for a particular set of fluorophores and X, values to optimize the system’s ability to easily distinguish the various fluorophores and simplify the analysis and/or improve confidence in the results.
  • aspects of the flow cytometer such as but not limited to the filters, laser intensities, detector gains, etc.
  • the system may require a threshold level of fluorescence. There may be certain events wherein the threshold level of fluorescence is met and the size of the target particle (e.g., cell) is appropriate but there is not an appropriate significantly dominant fluorophore. For example, while the system requires a dominant fluorophore as a constraint, the residual error for the best case may be exceptionally high, meaning it is not a good fit. In the aforementioned event, the system may ignore the event (e.g., cell) completely and not count it as anything. As a non-limiting example, this may be possible for fastidious pathogens that require a special component in the growth media to grow that will not be labeled in the final antibiotic susceptibility testing (AST) analysis.
  • AST antibiotic susceptibility testing
  • the sample if the total concentration of a cell type identified as a particular infectious agent is greater than a predetermined infection threshold, the sample is considered to be positive for that infectious agent. In some embodiments, if the total concentration of a cell type identified as a particular infectious agent is less than a predetermined infection threshold, the sample is considered to be negative for that infectious agent.
  • the infection threshold may be an industry standard, a laboratory standard, etc. For example, a commonly used infection threshold is 10 4 cells/ml; however, the present invention is not limited to this particular infection threshold. In some embodiments, if an infectious agent is below the infection threshold, the infectious agent may not necessarily be considered in further analysis.
  • the system can next perform an antibiotic susceptibility testing (AST) analysis.
  • AST antibiotic susceptibility testing
  • the system can utilize a database formed from historical data or data previously collected to predict the probability of susceptibility of the one or combination of infectious agents in the sample against various concentrations and/or various types of antimicrobial agents in an antibiotic susceptibility testing (AST) analysis, e.g., using an ABX plate, to determine which wells of the ABX plate are optimal to test, which ones are to be prioritized first, and which are likely unnecessary to analyze.
  • AST antibiotic susceptibility testing
  • the system may feature a multiwell plate (ABX plate) wherein a plurality of the wells house various individual antimicrobial agents at various particular concentrations or a combination of antimicrobial agents at particular concentrations.
  • the ABX plate may feature a series of concentrations of one or more of the following antimicrobial agents: Ciprofloxacin, Levofloxacin, Tetracycline, Cefaclor, Nitrofurantoin, Ampicillin, Sulfamethoxazole/Trimethoprim, Ceftriaxone, Gentamicin, Cefazolin, Cefepime, Cefoxitin, Cefazidinme, Meropenem, and/or Vancomycin.
  • the ABX plate may feature a series of concentrations of one or more of the following combinations of antimicrobial agents: Piperacillin/Tazobactam, Amoxicillin/Clavulanate, and/or Ampicillin/Sulbactam.
  • the present invention is not limited to the antimicrobial agents disclosed herein, nor the concentrations thereof.
  • Wells may also feature growth media disposed therein prior to inoculation with the sample.
  • a portion sample is prepared for AST analysis in growth media, and the antimicrobial agents are inoculated with aliquots of sample-growth media.
  • all of the wells are inoculated with a portion of the sample. In some embodiments certain wells are not inoculated if, for example, it has been predetermined, based on the identification of infectious agents, that the particular antimicrobial agent and/or concentration thereof will be irrelevant to the analysis.
  • the plate is then incubated for a nominal time which may be a function of the infectious agents identified in the prior step or may be a fixed nominal time.
  • the plate is removed from the incubator. In some embodiments, the plate is centrifuged and the supernatant is removed from each appropriate well.
  • an antibody cocktail is added which will have antibody conjugates for each pathogen of interest.
  • the antibody cocktail may not feature antibody conjugates directed to fastidious organisms, e.g., organisms that would not be likely to grow during the incubation in the growth media.
  • the antibody cocktail is added only to the wells that have not been predetermined to be excluded from analysis. The plate may then be allowed to incubate for a period of time.
  • the plate may then be prepared, As a non-limiting example, the plate may be centrifuged, the supernatant removed from the appropriate wells, wells resuspended with a wash buffer, etc. This centrifuge and resuspension may be repeated multiple times, e.g., once, 2x, 3x, 4x, 5x, etc. In some embodiments only the wells that have not been predetermined to be excluded from analysis will be prepared.
  • the system will analyze the ABX plate one well at a time, e.g., via flow cytometry.
  • concentration of the various target infectious agents will be determined and assessed as to whether sufficient growth has occurred to conclude that the given pathogen is resistant to the components of that well. If not, it is susceptible.
  • the system is configured to determine the antimicrobial agents and/or concentrations thereof to which the sample is susceptible and to which the sample is resistant. This allows the system to determine the minimum susceptible concentration of the relevant antimicrobial agents, e.g., the minimum inhibitory concentrations.
  • the system analyzes each of the wells seeded with the sample.
  • the system selects particular wells to analyze first. For example, the system may organize the wells in a particular order in which it intends to analyze based on one or more predictive criteria.
  • the results of one well may result in the changing of the order of the wells for the subsequent analysis. Some wells may not be analyzed based on the results of previously analyzed wells.
  • a database containing measured resistances and minimum inhibitory concentrations (MICs) of samples of various infectious agents and combinations of infectious agents (polymicrobial infections) against various concentrations of various antimicrobial agents or combinations of antimicrobial agent can be used to determine the probabilities of resistance (p R ) for individual infectious agents when exposed to the various concentrations of the various antimicrobial agents.
  • the PR can be used to select the order of well analysis that will result in the fewest wells needed to be analyzed in order to get the desired information, e.g., the minimum inhibitory concentration (MIC) for one or potentially all acceptable antimicrobial agents against a given pathogen.
  • a reason there are a range of probabilities may be due to the fact that there are multiple variants of each pathogenic species in the overall population due to slight genetic modifications over time.
  • a result may be that some species variants are inhibited at a given concentration while others are resistant at any viable concentration.
  • the identity of the pathogenic species may be known, in some embodiments, the particular variants can be harder to characterize and identify and thus may not be known. Using the known population statistics on resistance, the number of wells that must be analyzed in the ABX plate can be minimized.
  • the ABX plate may include 2 - 3 concentrations of each antimicrobial agent (or combination of antimicrobial agents) to be tested so as to allow for determination of the MIC. If the probability of resistance to a given antimicrobial agent at the highest concentration is high (but less than 100%, or 1) for a particular pathogen in a sample, then it may be most efficient to test this highest concentration first. If resistance is shown, which is the expected outcome, this resistance will eliminate that antimicrobial agent as a candidate without the need to test the other one or more smaller concentrations. If susceptible at that concentration, then the analysis can continue with the next lower concentration until the MIC is determined.
  • the course may be to test the lowest concentration well first. If susceptible, which is the expected outcome, then there is no reason to test the other one or more concentrations as the MIC has been established. If the p R values of a pathogen across a range of concentrations of an antimicrobial agent are such that 0 ⁇ p R ⁇ 1 then, in the case of 3 concentrations it may be the best course to start with the middle concentration.
  • the best course may be to start with the concentration that is most likely to sit at the edge of the resistance/susceptibility probability border and then follow with the increased or decreased concentration depending on detection of resistance or susceptibility respectively in order to estabfish the MIC.
  • the present invention includes the possibility that the infection in the sample is a polymicrobial infection, e.g., two or more different infectious agents.
  • the pRs are calculated based on the identity of the two or more different infectious agents and the susceptibility and resistance data of the combination of the infectious agents.
  • the present invention is not limited to the use of just the overall population statistics. Conditional probabilities can be used to further minimize the number of wells needed to be tested. For example, there may be some variations in pathogens that make them more resistant or susceptible to the mechanism of a certain antimicrobial action.
  • the p R of a pathogen against a certain antimicrobial agent at its highest concentration may be, as an example, 0.5 (for this example referred to as PR(B)). If it is measured to be resistant or susceptible at that highest concentration, that data may help provide some information about what variant it is (even if it is not named), and it may thereafter be considered a variant that is now known to be resistant or susceptible based on the observed measure.
  • conditional probability (probability of it being resistant to A given it is known that it is resistant to B) may be different than the overall observed probability PR(A) due to factors that relate them (rather than being independent) such as, but not limited to, that the compounds in a class of antimicrobial agents may have similar inhibitory mechanisms and may be similarly affected by the change in the variant among other factors.
  • factors that relate them such as, but not limited to, that the compounds in a class of antimicrobial agents may have similar inhibitory mechanisms and may be similarly affected by the change in the variant among other factors.
  • identifying these antimicrobial agents (B) for which the conditional probabilities of other antimicrobial agents inhibiting that pathogen are changed dependent on the result can provide leverage to improve the efficiency of the plate analysis.
  • the antimicrobial agents instead of traversing the plate as indicated above, it may be best to target the antimicrobial agents that provide the most leverage in understanding the true probabilities of resistance against other agents given its susceptibility or resistance and then use that new information to optimize the analysis (minimize the wells visited/analyzed) as discussed above.
  • the system may feature a preparation unit, e.g., a component of the system that prepares a sample for analysis (e.g., spin, wash, resuspend, etc.); an analysis unit, e.g., a flow cytometry system, a component of the system that may identify one or more infectious agents in the sample, quantify one or more infectious agents in the sample, identify one or more markers on or in the infectious agents in the sample, etc.; and/or an incubation unit, e.g., a component of the system that may function to store, hold, retain, or promote the growth of the sample (e.g., the infectious agents in the sample), such as an incubator.
  • a preparation unit e.g., a component of the system that prepares a sample for analysis (e.g., spin, wash, resuspend, etc.)
  • an analysis unit e.g., a flow cytometry system, a component of the system that may identify one or more infectious agents in the sample, quantify one or more
  • the preparation unit and/or analysis unit and/or incubation unit may be operatively linked, e.g., wherein a sample can be moved from one unit to another as is appropriate.
  • the sample is preprocessed prior to insertion into the system.
  • a sample may be inserted into the preparation unit. From the preparation unit, the sample may move to the incubation unit. In certain embodiments, the sample moves from the incubation unit back to the preparation unit. The sample may then move from the preparation unit to the analysis unit to be analyzed. In some embodiments, the sample moves from the analysis unit back to the preparation unit. There may be certain embodiments wherein circumstances allow for the sample to move from the incubation unit to the analysis unit directly.
  • the systems of the present invention also feature components for transporting the sample or a portion thereof from one unit to another, e.g., from the preparation unit to the analysis unit, from the analysis unit to the incubation unit, from the preparation unit to the incubation unit, from the incubation unit to the analysis unit, etc.
  • the systems of the present invention may also provide reagents, e.g., buffers, growth media, dyes, labels, etc., for various steps, tests, and methods associated with the preparation unit, analysis unit (e.g., flow cytometry unit), and incubation unit.
  • reagents e.g., buffers, growth media, dyes, labels, etc.
  • the systems of the present invention also feature components for storing, manipulating, and administering said reagents, e.g., buffers, growth media, dyes, labels, etc.
  • the present invention is not limited to the particular fluorophores disclosed herein (or particular fluorophore conjugates), and alternative fluorophores are well known to one of ordinary skill in the art and within the scope of this invention.
  • FIG. 2 shows a non-limiting example of a system of the present invention and a plurality of components and reagents included therein.
  • the system in FIG. 2 features growth media containers (e.g., various for different media), stain cocktail containers (e.g., various), cleaning liquid container(s), buffer containers (e.g., various, e.g., bead wash buffer, sample wash buffer, etc.), a tip wash station, a waste disposal tank, a bar code scanner, one or more incubators, stages or locations for samples or multiwell plates, a centrifuge, a cytometer analysis unit, storage (e.g., for ID plates, ABX plates, sample tubes, tips, etc.), etc.
  • growth media containers e.g., various for different media
  • stain cocktail containers e.g., various
  • buffer containers e.g., various, e.g., bead wash buffer, sample wash buffer, etc.
  • a tip wash station e.g
  • the systems of the present invention also feature computer-implemented instructions for performing the automated methods herein.
  • the systems of the present invention also feature computer-implemented instructions for analyzing signals obtained from one or more sensors and/or detectors associated with the systems.
  • the systems and methods of the present invention may allow for the detection of at least 20 different target particles (e.g., cells or other particles such as but not limited to infectious agents), or at least 25 target particles, at least 30 target particles, at least 35 target particles, at least 40 target particles, etc.
  • the system may feature the use of at least 20 different antibodies or binding agents, or at least 25, at least 30, at least 35, etc., each specific for a particular target particle in the sample.
  • the system can also feature the detection of at least 40 different target particles (thus at least 40 different antibodies) using 5-30 labels or dyes.
  • the systems may be capable of at least 10,000 events per second, allowing for rapid and comprehensive analysis of samples.
  • the present invention is not limited to 10,000 events per second.
  • the event rate may be higher than 10,000 events per second, e.g., 20,000 events per second, 30,000 events per second, more than 30,000 events per second, etc.
  • the system can process at least 2 samples per day. In some embodiments, the system can process at least 5 samples per day. In some embodiments, the system can process at least 10 samples per day. In some embodiments, the system can process at least 15 samples per day. In some embodiments, the system can process at least 20 samples per day. In some embodiments, the system can process at least 25 samples per day. In some embodiments, the system can process at least 30 samples per day. In some embodiments, the system can process at least 35 samples per day. In some embodiments, the system can process at least 40 samples per day. In some embodiments, the system can process at least 45 samples per day. In some embodiments, the system can process at least 50 samples per day.
  • the system can process at least 55 samples per day. In some embodiments, the system can process at least 60 samples per day. In some embodiments, the system can process at least 65 samples per day. In some embodiments, the system can process at least 70 samples per day. In some embodiments, the system can process at least 75 samples per day. In some embodiments, the system can process at least 80 samples per day. In some embodiments, the system can process at least 85 samples per day. In some embodiments, the system can process at least 90 samples per day. In some embodiments, the system can process at least 95 samples per day. In some embodiments, the system can process at least 100 samples per day.
  • the system of the present invention may comprise a preparation unit, e..g, a component of the system that prepares a sample for flow cytometry analysis in the analysis unit and/or incubation in the incubation unit.
  • a preparation unit e..g, a component of the system that prepares a sample for flow cytometry analysis in the analysis unit and/or incubation in the incubation unit.
  • a raw sample is inserted directly into the system.
  • the sample is processed in some manner prior to insertion into the system.
  • samples are cleaned and concentrated.
  • the samples are spun to create a pellet, washed, and resuspended in a medium prior to being transported to the analysis unit.
  • Methods for cleaning and concentrating samples are known to one of ordinary skill in the art.
  • the preparation unit comprises a centrifuge, a holding tank for wash buffer, and a holding tank for resuspension buffer.
  • the preparation unit comprises a magnetic bead separation rack.
  • the preparation unit may further comprise a sample input component for accepting raw samples.
  • the preparation unit further comprises tubing and/or hydraulics for aspirating media and/or wash buffer, and/or for introducing wash buffer and/or resuspension buffer to the pelleted samples.
  • the preparation unit is not limited to the aforementioned components and/or configurations.
  • the preparation unit may allow for concentration of the sample and subsequent dilution.
  • the preparation unit provides the concentration of the sample.
  • the analysis unit provides the concentration of the sample. Knowledge of the initial concentration of the resuspended sample may help allow for the determination of antibiotic susceptibility and resistance of the sample (e.g., after processing in the incubation unit, for example).
  • the system of the present invention comprises an analysis unit, e.g., a component of the system that identifies one or more infectious agents, and/or quantifies one or more infectious agents, etc.
  • the analysis unit may comprise one or more flow cytometers or flow cytometry-like devices.
  • the systems comprise a plurality of flow cytometry-like devices, e.g., two or more, three or more, four or more, etc.
  • the system may comprise three flow devices.
  • flow cytometry can be used to measure one or more optical or electrical parameters of infectious agents that pass through a light beam (e.g., a laser).
  • a light beam e.g., a laser
  • a fluid sample to be analyzed is introduced from a sample tube into or near the center of a faster flowing stream of sheath fluid.
  • the sample is compressed, causing the infectious agents in the sample volume to be columnated and be delivered to the center of the measuring point in an examination zone.
  • a laser beam is focused on the infectious agents as they pass through the examination zone.
  • Detectors that are optically connected to the examination zone interrogate signals from this zone on one or more detection channels. When an infectious agent in the flow stream is struck by the laser beam, certain signals are generated and sensed by detectors.
  • the detectors utilize a plurality of detection channels and there may be multiple lasers of differing wavelengths spatially separated along the flow path to create multiple examination zones.
  • signals include forward scatter intensity, which provides information concerning the size of individual infectious agents, side scatter intensity, which provides information regarding the granularity (relative size, proportions, and refractive properties) of the infectious agents, and fluorescence emissions from one or more fluorescent dyes and/or fluorescent molecules associated with the infectious agents.
  • the system comprises components for measuring and/or introducing reagents to the sample.
  • the analysis unit may comprise a component for introducing one or a combination of antibodies (or binding fragments) conjugated with detectable labels or dyes, wherein the antibodies or binding fragments are specific for a single infectious agent.
  • the conjugated antibodies (or binding fragments) allow for specific identification of the infectious agents.
  • the system uses at least 5 conjugated antibodies (or binding fragments) for the identification of 5 infectious agents. In some embodiments, the system uses at least 10 conjugated antibodies (or binding fragments) for the identification of 10 infectious agents. In some embodiments, the system uses at least 20 conjugated antibodies (or binding fragments) for the identification of 20 infectious agents. In some embodiments, the system uses at least 30 conjugated antibodies (or binding fragments) for the identification of 30 infectious agents. In some embodiments, the system uses at least 40 conjugated antibodies (or binding fragments) for the identification of 40 infectious agents.
  • the systems of the present invention are configured to detect and identify small particles such as viruses.
  • Methods and systems for viral detection using flow cytometry e.g., flow virometry
  • the systems use labeled (e.g., fluorescently labeled) specific binding agents (e.g., antibodies, antibody fragments, etc.) for specific detection of viral particles.
  • labeled specific binding agents e.g., antibodies, antibody fragments, etc.
  • the present invention is not limited to the use of labeled specific binding agents and may include staining procedures or other methods for specific viral detection.
  • the present invention is not limited to the detection of specific infectious agents in the sample.
  • the systems of the present invention are configured to enumerate the infectious agents present in the sample.
  • the systems of the present invention are configured to distinguish (and quantitate) live and dead infectious agents present in the sample.
  • Methods and reagents for enumerating infectious agents such as bacteria are well known as one of ordinary skill in the art.
  • commercially available reagents for enumerating bacteria include nucleic acid stains that penetrate both Gram-positive and Gram-negative bacteria, e.g., SYTO BC dye (ThermoFisher Scientific).
  • reagents for distinguishing (and quantitating) live and dead infectious agents are well known to one of ordinary skill in the art.
  • commercially available reagents include propidium iodide, SYTO 9 dye (ThermoFisher Scientific), redox indicators for determining whether or not the cells are alive, e.g., CellROX (ThermoFisher Scientific), etc.
  • the present invention is not limited to the aforementioned reagents.
  • the systems are configured to identify active infections using markers for red blood cells (RBCs).
  • the systems are configured to detect other cell types and/or other particles.
  • the systems are configured to detect white blood cells.
  • the system may be designed to determine which elements (e.g., which well of the microplate) to analyze based on ID, prior sample data (e.g., from a database), and/or the previous well’s results. This helps minimize the time needed for analysis.
  • the system of the present invention comprises an incubation unit, e.g., a component of the system that may function to store, hold, retain, or promote the growth of the sample (e.g., the infectious agents in the sample).
  • the incubation unit may comprise one or a combination of incubators for allowing for growth of infectious agents in the sample.
  • the incubators may be set to facilitate growth under particular conditions.
  • the incubation unit comprises an incubator in aerobic conditions.
  • the incubation unit comprises an incubator in anaerobic conditions.
  • Samples may be incubated in the incubation unit for a time frame.
  • the time frame is dependent on which infectious agents are detected by the analysis unit.
  • the time frame is 1 minute. In some embodiments, the time frame is 5 minutes. In some embodiments, the time frame is 8 minutes. In some embodiments, the time frame is 10 minutes. In some embodiments, the time frame is 20 minutes. In some embodiments, the time frame is 30 minutes. In some embodiments, the time frame is 60 minutes. In some embodiments, the time frame is 1.5 hours. In some embodiments, the time frame is 2 hours. In some embodiments, the time frame is 2.5 hours. In some embodiments, the time frame is 3 hours. In some embodiments, the time frame is 4 hours.
  • the time frame is 5 hours. In some embodiments, the time frame is 6 hours. In some embodiments, the time frame is 6 or more hours. In some embodiments, the time frame is 9 or more hours. In some embodiments, the time frame is 12 hours. In some embodiments, the time frame is 12 or more hours. In some embodiments, the time frame is from 1-10 minutes. In some embodiments, the time frame is from 5-20 minutes. In some embodiments, the time frame is from 10-30 minutes. In some embodiments, the time frame is from 10-60 minutes. In some embodiments, the time frame is from 30-60 minutes. In some embodiments, the time frame is from 1 to 2 hours. In some embodiments, the time frame is from 2 to 4 hours. In some embodiments, the time frame is from 4 to 6 hours. In some embodiments, the time frame is from 6 to 9 hours. In some embodiments, the time frame is from 9 to 12 hours. In some embodiments, the time frame is more than 12 hours.
  • a portion of the sample may be inoculated in a growth medium and incubated in aerobic conditions at a particular temperature, e.g., 37 degrees, for a time frame.
  • the incubated sample may be incubated in anaerobic conditions at a particular temperature, e.g., 37 degrees, for a time frame.
  • a portion of the sample may be inoculated in a growth medium comprising an antibiotic or antimicrobial agent. In certain embodiments, a portion of the sample may be inoculated in a growth medium comprising one or more antibiotics or antimicrobial agents. In certain embodiments, a portion of the sample may be inoculated in a growth medium comprising two or more antibiotics or antimicrobial agents. In certain embodiments, a portion of the sample may be inoculated in a growth medium comprising three or more antibiotics or antimicrobial agents.
  • the preparation unit comprises components that measure and/or aliquot portions of the sample into one or more wells of a multiwell plate; alternatively, in some embodiments, the incubation unit comprises components that measure and/or aliquot portions of the sample into one or more wells of a multiwell plate.
  • the incubation unit may further comprise components for moving the multiwell plates in and out of the appropriate incubator, or receiving the sample from the preparation unit, or transporting the sample to the preparation unit, etc.
  • the systems of the present invention are configured to determine the antibiotic susceptibility of infectious agents present in the sample.
  • Samples, after incubation, may be redirected to the analysis unit for testing.
  • the samples return to the preparation unit prior to being redirected to the analysis unit.
  • the sample comprises a single infectious agent. In some embodiments, the sample comprises 2 or more infectious agents. In some embodiments, the sample comprises 3 or more infectious agents. In some embodiments, the sample comprises 4 or more infectious agents. In some embodiments, the sample comprises 5 or more infectious agents. In some embodiments, the sample comprises 6 or more infectious agents. In some embodiments, the sample comprises 7 or more infectious agents.
  • the system can process a sample (referring to the identification process, e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within 15 minutes.
  • the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within 20 minutes.
  • the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within 30 minutes.
  • the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within 45 minutes. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within one hour. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within two hours.
  • a sample e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any
  • the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within three hours. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within four hours. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within five hours.
  • a sample e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any
  • the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within six hours. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within seven hours. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within eight hours.
  • a sample e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any
  • the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within nine hours. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within ten hours. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within twelve hours. In some embodiments, the system can process a sample (e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample, if any) within 24 hours.
  • a sample e.g., obtain the sample, subject the sample to the preparation unit
  • the system can process a sample, e.g., obtain the sample, subject the sample to the preparation unit and analysis unit, and provide information related to the identification and quantification of infectious agents present in the sample and if positive generate the AST results within 4-6 hours.
  • the system can process at least 1 sample per day. In some embodiments, the system can process at least 2 samples per day. In some embodiments, the system can process at least 3 samples per day. In some embodiments, the system can process at least 4 samples per day. In some embodiments, the system can process at least 5 samples per day. In some embodiments, the system can process at least 8 samples per day. In some embodiments, the system can process at least 10 samples per day. In some embodiments, the system can process at least 15 samples per day. In some embodiments, the system can process at least 20 samples per day. In some embodiments, the system can process at least 25 samples per day. In some embodiments, the system can process at least 50 samples per day.
  • FIG. 3 and FIG. 4 show and describe embodiments of the system of the present invention.
  • a sample e.g., contained in a tube or vessel
  • the instrument e.g., a stage.
  • the sample tubes feature a barcode for identification.
  • the system may feature a barcode reader that reads the barcode of the sample and enters it into the database (e.g., of the computer system, e.g., the processing and memory units, etc.).
  • the sample may be moved from the stage to a different location where it is mixed and aliquoted to wells of a multiwell plate.
  • the present invention is not limited to a particular type or size of multiwell plate.
  • the system houses the multiwell plates in a storage container and obtains one of the plates as needed.
  • a user loads the system with the multiwell plate to be used for the specific sample when needed.
  • the sample tube (and any leftover sample) may be discarded after the appropriate amount of sample has been aliquoted into the wells of the multiwell plate.
  • the plate may be transported from its location to a centrifuge to be spun, after which the plate is removed from the centrifuge and transported to a location where supernatant is aspirated (and discarded) and growth media is added to the appropriate wells (e.g., some of the wells) of the plate in preparation for preculture incubation.
  • one or a combination of wells resuspended with growth media are mixed and then transferred to a new sample tube (optionally certain wells may be combined together and transferred into one new sample tube), e.g., a pre-culture tube.
  • a pre-culture tube is transported to the incubator for a period of time.
  • the system may aliquot staining cocktails to the appropriate wells of the multiwell plate and perform serial dilutions for each set of cocktails used to provide more dilute samples in the case that the infectious agents are initially present in too high of a concentration for analysis.
  • the plate is incubated at room temperature for a period of time. When ready, the plate may be centrifuged, the supernatant aspirated, and wash solution added; this set of steps may be repeated.
  • the plate may be transferred to the flow cytometer for determining identities of the infectious agents in the sample. For example, the system may start with analysis of the most dilute wells for each cocktail used and either use that well for the analysis or use said well for determining which well is best for analysis. The results of the flow cytometry analysis may help determine if the sample should be subjected to antibiotic susceptibility testing.
  • the sample pre-culture tube in the incubator may be discarded.
  • growth media may be plated into various wells of a multiwell plate (e.g., an ABX plate).
  • a multiwell plate e.g., an ABX plate.
  • the pre-culture tube from the incubator is accessed and the sample is aliquoted into various wells as appropriate. If the concentration of the sample is too high, the sample may be diluted prior to inoculation of the wells.
  • the ABX plate may be returned to the incubator for a period of time.
  • the ABX plate is retrieved and subjected to centrifugation, a wash step, and resuspension; this series of steps may be repeated if needed. Staining cocktails may be added to particular wells as appropriate and mixed. The plate may be incubated at room temperature for a period of time. In certain embodiments, the ABX plate is retrieved and subjected to centrifugation, a wash step, and resuspension; this series of steps may be repeated. After said preparation, the ABX plate is transferred to the cytometer for analysis for susceptibility.
  • the system may be configured to minimize the number of wells analyzed by the flow cytometer based on the initial identification of the infectious agent and prioritization of wells analyzed by leveraging results from all wells analyzed for that sample.
  • the end result is a determination of MIC for the various antimicrobial agents or combinations thereof which inhibit the growth of the infectious agents in the sample.
  • the organisms capable of being detected are one or a combination of: Acinetobacter baumannii, Actinobaculum schaalii, Aerococcus urinae, Alloscardovia omnicolens, Candida albicans, Candida glabrata, Candida parapsilosis, Citrobacter koseri, Citrobacter freundii, Corynebacterium riegelii, Enterococcus faecalis, Enterobacter aerogenes, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Mycoplasma hominis, Pantoea agglomerans, Proteus mirabilis, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus
  • the sample is a urine sample being tested for a urinary tract infection.
  • the following antibody conjugates are used: monoclonal antibody against E. coli antigen conjugated with Super Bright 436; monoclonal antibody against S. oralis antigen conjugated with Alexa Fluor 488; monoclonal antibody against C. freundii antigen conjugated with PE-Cyanine7; monoclonal antibody against E. faecalis antigen conjugated with Super Bright 600; monoclonal antibody against S. aureus antigen conjugated with NovaFluor Yellow 610; monoclonal antibody against C. alibicans antigen conjugated with Alexa Fluor 647; monoclonal antibody against A. schaalii antigen conjugated with Alexa Fluor 700; monoclonal antibody against S epidermidis antigen conjugated with SuperBright 702; monoclonal antibody against K pneumoniae antigen conjugated with APC-eFluor 780.
  • the present invention is not limited to the aforementioned fluorophores or aforementioned antibody-fluorophore conjugates, and alternative fluorophores are well known to one of ordinary skill in the art and are within the scope of this invention.
  • the present invention is not limited to analysis of bacteria.
  • Other infectious agents or other targets of interest including antigens, particles, viruses, other cells, etc., may also be subject to analysis using the system of the present invention.
  • the sample After the sample has been identified in the computer system, the sample is moved from the stage to a different location where it is mixed and aliquoted to four of the wells of a multiwell deep well plate.
  • the plate is transported from its location to a centrifuge to be spun, after which the plate is removed from the centrifuge and transported to a location where supernatant is aspirated (and discarded) and growth media is added to two of the wells of the plate in preparation for preculture incubation.
  • the wells resuspended with growth media are mixed and then transferred to a single new sample tube, e.g., a pre-culture tube.
  • the pre-culture tube is transported to the incubator for a period of time.
  • the system aliquots two staining cocktails separately into each of the two remaining sample wells and two each of four additional empty wells of the multiwell plate and perform serial dilutions of the two sample wells for each set of cocktails used to provide more dilute samples in the case that the infectious agents are initially present in too high of a concentration for analysis.
  • the plate is incubated at room temperature for a period of time. After incubation, the plate is centrifuged, the supernatant aspirated, and wash solution added; this set of steps is repeated two more times.
  • the plate is transferred to the flow cytometer for determining identities of the infectious agents in the sample.
  • the system starts with analysis of the most dilute wells for each cocktail used and either use that well for the analysis or use said well for determining which well is best for analysis and then analyze that well.
  • the result of this flow cytometry analysis indicates the following infectious agents are detected at infectious levels, e.g., at concentrations above the infection threshold: E. coli at 8x 10 4 cells/ml and E.faecalis at 6x10 6 cells/ml.
  • Previously collected data in a database is used to predict the probability of susceptibility against the various concentrations and types of antimicrobial agents in the ABX plate to determine which wells are optimal to test and which are likely unnecessary to analyze.
  • the system will next perform antibiotic susceptibility testing (AST).
  • AST antibiotic susceptibility testing
  • the system features a multiwell plate (ABX plate) wherein a plurality of the wells house various individual antimicrobial agents at various particular concentrations or a combination of antimicrobial agents at particular concentrations.
  • the ABX plate may feature a series of concentrations of one or more of the following antimicrobial agents: Ciprofloxacin, Levofloxacin, Tetracycline, Cefaclor, Nitrofurantoin, Ampicillin, Sulfamethoxazole/Trimethoprim, Ceftriaxone, Gentamicin, Cefazolin, Cefepime, Cefoxitin, Ceftazidime, Meropenem, and/or Vancomycin.
  • the ABX plate may feature a series of concentrations of one or more of the following combinations of antimicrobial agents: Piperacillin/Tazobactam, Amoxicillin/Clavulanate, and/or Ampicillin/Sulbactam.
  • FIG. 3 A non-limiting example of an ABX plate with its series of concentrations of particular antimicrobial agents is shown in FIG. 3.
  • Growth media is plated into various wells of a multiwell plate (e.g., an ABX plate).
  • a multiwell plate e.g., an ABX plate.
  • the pre-culture tube from the incubator is accessed and the sample is aliquoted into various wells as appropriate. If the concentration of the sample is too high, the sample may be diluted prior to inoculation of the wells.
  • the ABX plate may be returned to the incubator for a period of time.
  • the ABX plate is retrieved and subjected to centrifugation, a wash step, and resuspension.
  • a staining cocktail is added to particular wells as appropriate and mixed.
  • the plate is incubated at room temperature for a period of time.
  • the ABX plate is retrieved and subjected to centrifugation, a wash step, and resuspension; this series of steps is repeated twice.
  • the ABX plate is transferred to the cytometer for analysis for susceptibility.
  • the system analyzes the results of the AST.
  • the AST analysis provides information related to the antimicrobial agents to which the sample is susceptible and the antimicrobial agents to which the sample is resistant.
  • the AST analysis also provides minimum inhibitory concentrations (MICs).
  • the following example provides additional non-limiting examples of antibody conjugates: monoclonal antibody against Streptococcus anginosus antigen conjugated with StarBright Violet 515; monoclonal antibody against Viridans Group Streptococcus antigen conjugated with FITC; monoclonal antibody against M. genitalium antigen conjugated with YFP; monoclonal antibody against P. stuartii antigen conjugated with PE-Alexa Fluor 750; monoclonal antibody against A. baumannii antigen conjugated with DyLight 650; monoclonal antibody against C.
  • glabrata antigen conjugated with mCherry monoclonal antibody against HHV-7 antigen conjugated with PerCP-Cy5.5; monoclonal antibody against Adenovirus antigen conjugated with StarBright Blue 700; monoclonal antibody against K. oxytoca antigen conjugated with Brilliant Violet 711.
  • Additional non-limiting examples of antibody conjugates may include: monoclonal antibody against Chlamydia antigen conjugated with PE-Cyanine 5.5; monoclonal antibody against 5. marcescens antigen conjugated with EGFP; monoclonal antibody against BK Virus antigen conjugated with StarBright Violet 440; monoclonal antibody against C. glabrata antigen conjugated with Pacific Blue; monoclonal antibody against Coagulase-negative Staphylococcus antigen conjugated with PerCP; monoclonal antibody against M. hominis antigen conjugated with Alexa Fluor 405; monoclonal antibody against T. vaginalis antigen conjugated with APC-Cy7; monoclonal antibody against U ureafyticum antigen conjugated with RFP; monoclonal antibody against P. mirabilia antigen conjugated with DyLight 550.
  • An example protocol in the application of the systems herein includes, but is not limited to: (1) introducing a sample to the system for identification by placing the sample contained within a tube (e.g., initial sample tube) onto the system and scanning the identifying barcode and entering it into a system database; (2) performing pre-culture preparation and incubation of the sample by mixing and transferring the sample contained within the initial sample tube to an identification plate, centrifuging the identification plate and disposing of the supernatant, adding fresh growth media to each well and mixing and dispensing the contents of the pre-culture wells into a clean tube (e.g., pre-culture tube) for incubation at 37 degrees Celsius for a period of time; (3) performing sample identification preparation steps by staining the sample wells and executing a serial dilution before allowing the identification
  • Embodiments of the present invention can be freely combined with each other if they are not mutually exclusive.
  • descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting essentially of’ or “consisting of’, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting essentially of’ or “consisting of’ is met.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Des méthodes et des systèmes fondés sur la cytométrie en flux permettent d'identifier rapidement une particule cible, telle qu'une cellule cible, une particule cible, ou de multiples cellules cibles ou particules cibles distinctes. Les méthodes et les systèmes de l'invention permettent de distinguer et d'identifier de multiples cellules cibles ou particules cibles distinctes provenant d'un seul échantillon contenant une pluralité de cibles. Les méthodes et les systèmes de l'invention peuvent être utilisés pour des applications comprenant entre autres l'identification et la quantification d'agents infectieux, par exemple des bactéries, des virus, des champignons, des parasites, etc. dans un échantillon.
PCT/US2022/077477 2021-10-01 2022-10-03 Méthodes et systèmes automatisés d'identification rapide de particules cibles WO2023056481A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163251433P 2021-10-01 2021-10-01
US63/251,433 2021-10-01
US202263329757P 2022-04-11 2022-04-11
US63/329,757 2022-04-11

Publications (1)

Publication Number Publication Date
WO2023056481A1 true WO2023056481A1 (fr) 2023-04-06

Family

ID=85780918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/077477 WO2023056481A1 (fr) 2021-10-01 2022-10-03 Méthodes et systèmes automatisés d'identification rapide de particules cibles

Country Status (1)

Country Link
WO (1) WO2023056481A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150198584A1 (en) * 2014-01-14 2015-07-16 Asedasciences Ag Identification of functional cell states
US20200209064A1 (en) * 2018-12-28 2020-07-02 Becton, Dickinson And Company Methods for spectrally resolving fluorophores of a sample and systems for same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150198584A1 (en) * 2014-01-14 2015-07-16 Asedasciences Ag Identification of functional cell states
US20200209064A1 (en) * 2018-12-28 2020-07-02 Becton, Dickinson And Company Methods for spectrally resolving fluorophores of a sample and systems for same

Similar Documents

Publication Publication Date Title
US8911987B2 (en) System for rapid identification and/or characterization of a microbial agent in a sample
EP2430461B2 (fr) Instrument de détection combiné pour récipients à échantillons de culture et instrument pour l'identification et/ou la caractérisation d'un agent microbien dans un échantillon
US9611501B2 (en) Method and device for rapid detection of bacterial antibiotic resistance/susceptibility
US20230235411A1 (en) Microbial analysis without cell purification
WO2023056481A1 (fr) Méthodes et systèmes automatisés d'identification rapide de particules cibles
JP7127033B2 (ja) デジタル顕微鏡を使用する抗菌剤感受性試験
US20220340952A1 (en) Rapid antimicrobial susceptibility testing by image analysis
Andrade et al. A rapid flow cytometric antimicrobial susceptibility assay (FASTvet) for veterinary use–preliminary data
WO2004090089A1 (fr) Systeme pour une identification de micro-organismes et un test antibacterien rapides
Gupta et al. Automation Techniques in Aerobic Bacteriology

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22877652

Country of ref document: EP

Kind code of ref document: A1